BioLineRx (BLRX) Liabilities and Shareholders Equity (2021 - 2025)

BioLineRx has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $40.9 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $40.9 million for Q4 2025, up 5.14% from a year ago — trailing twelve months through Dec 2025 was $220.1 million (down 15.54% YoY), and the annual figure for FY2025 was $40.9 million, up 5.14%.
  • Liabilities and Shareholders Equity for Q4 2025 was $40.9 million at BioLineRx, up from $38.9 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BLRX hit a ceiling of $81.4 million in Q4 2021 and a floor of $38.9 million in Q4 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $63.9 million (2023), compared with a mean of $60.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 39.14% in 2024 and later rose 5.14% in 2025.
  • BioLineRx's Liabilities and Shareholders Equity stood at $81.4 million in 2021, then decreased by 6.15% to $76.4 million in 2022, then decreased by 16.31% to $63.9 million in 2023, then tumbled by 39.14% to $38.9 million in 2024, then rose by 5.14% to $40.9 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $40.9 million (Q4 2025), $38.9 million (Q4 2024), and $63.9 million (Q4 2023) per Business Quant data.